Literature DB >> 8447521

Tolerance and efficacy of single high-dose ivermectin for the treatment of loiasis.

Y Martin-Prevel1, J Y Cosnefroy, P Tshipamba, P Ngari, J A Chodakewitz, M Pinder.   

Abstract

A study was carried out in southeastern Gabon to evaluate the tolerance and efficacy of single high doses of ivermectin in 31 Loa loa-infected subjects with low-to-moderate parasitemia (7-7,700 microfilaria/ml). The first group of 16 subjects received 300 micrograms/kg of ivermectin and, seven days later, a second group of 15 received 400 micrograms/kg. Complete clinical and biological monitoring was carried out during the first 10 days post-treatment and again after one and three months. All subjects continued with their usual activities during the study. The clinical tolerance of treatment was very good, and except in one case, only mild adverse reactions were observed, with pruritus being the most common symptom. There were no significant changes in blood or urine function test results or in hematologic results, except for a pronounced eosinophil reaction. The 400 micrograms/kg dose of ivermectin equaled or surpassed in tolerance that of 300 micrograms/kg dose. After treatment, L. loa microfilaremia decreased rapidly to less than 9% of the pretreatment value by day 10. This decrease was enhanced with the 400 micrograms/kg dose, although differences between the two groups diminished slightly with time. At 100 days post-treatment, the microfilaremia was still at less than 10% of the initial values in the two groups, which may indicate an effect of ivermectin on the adult worms.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8447521     DOI: 10.4269/ajtmh.1993.48.186

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  11 in total

Review 1.  Pharmacotherapy of ectoparasitic infections.

Authors:  T C Roos; M Alam; S Roos; H F Merk; D R Bickers
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Posttreatment Reactions After Single-Dose Diethylcarbamazine or Ivermectin in Subjects With Loa loa Infection.

Authors:  Jesica A Herrick; Fanny Legrand; Raceline Gounoue; Godwin Nchinda; Céline Montavon; Jean Bopda; Steve Mbickmen Tchana; Bienvenu Etogo Ondigui; Konrad Nguluwe; Michael P Fay; Michelle Makiya; Simon Metenou; Thomas B Nutman; Joseph Kamgno; Amy D Klion
Journal:  Clin Infect Dis       Date:  2017-04-15       Impact factor: 9.079

Review 3.  Anthelmintics. A comparative review of their clinical pharmacology.

Authors:  N de Silva; H Guyatt; D Bundy
Journal:  Drugs       Date:  1997-05       Impact factor: 9.546

4.  [Bilateral subconjunctival foreign bodies. Loiasis with bilateral Loa ophthalmia].

Authors:  J Stammen; M Klüppel
Journal:  Ophthalmologe       Date:  2002-04       Impact factor: 1.059

5.  Assessment of loiasis and outcomes of ivermectin masstreatment in Ijebu-North, Nigeria.

Authors:  A A Hassan; B Akinsanya; N Iyase; F O Owagboriaye
Journal:  Korean J Parasitol       Date:  2011-06-14       Impact factor: 1.341

6.  African eye worm.

Authors:  Etienne Rivière; Julien Kerautret; France Combillet; Denis Malvy
Journal:  J Glob Infect Dis       Date:  2012-04

7.  Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon.

Authors:  Michel Boussinesq; Jacques Gardon; Nathalie Gardon-Wendel; Jean-Philippe Chippaux
Journal:  Filaria J       Date:  2003-10-24

8.  Ivermectin susceptibility and sporontocidal effect in Greater Mekong Subregion Anopheles.

Authors:  Kevin C Kobylinski; Ratawan Ubalee; Alongkot Ponlawat; Chanyapat Nitatsukprasert; Siriporn Phasomkulsolsil; Thanaporn Wattanakul; Joel Tarning; Kesara Na-Bangchang; Patrick W McCardle; Silas A Davidson; Jason H Richardson
Journal:  Malar J       Date:  2017-07-07       Impact factor: 2.979

9.  Ivermectin treatment of Loa loa hyper-microfilaraemic baboons (Papio anubis): Assessment of microfilarial load reduction, haematological and biochemical parameters and histopathological changes following treatment.

Authors:  Samuel Wanji; Ebanga-Echi J Eyong; Nicholas Tendongfor; Che J Ngwa; Elive N Esuka; Arnaud J Kengne-Ouafo; Fabrice R Datchoua-Poutcheu; Peter Enyong; Dalen Agnew; Rob R Eversole; Adrian Hopkins; Charles D Mackenzie
Journal:  PLoS Negl Trop Dis       Date:  2017-07-07

10.  Management of Malignant Wound Myiasis with Ivermectin, Albendazole, and Clindamycin (Triple Therapy) in Advanced Head-and-Neck Cancer Patients: A Prospective Observational Study.

Authors:  Bhavna C Patel; Shrenik Ostwal; Priti R Sanghavi; Geeta Joshi; Richa Singh
Journal:  Indian J Palliat Care       Date:  2018 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.